5-year outlook - risk scale up to 7/10
#LiCycle LICY (NYSE) #Cylib #Altilium Group Ltd. UK Scandinavian Enviro Systems AB Climate One Pty Ltd.
Allegrow Biotech Hong Kong #GreatBayBio Bioeconomy Corp. #Acepodia Heartseed
egal.space/blog/investi...
#LiCycle LICY (NYSE) #Cylib #Altilium Group Ltd. UK Scandinavian Enviro Systems AB Climate One Pty Ltd.
Allegrow Biotech Hong Kong #GreatBayBio Bioeconomy Corp. #Acepodia Heartseed
egal.space/blog/investi...
Investing in medical diagnostics and biotechnology vs. recycling
5-year outlook - risk scale up to 7/10
egal.space
January 30, 2026 at 12:13 PM
5-year outlook - risk scale up to 7/10
#LiCycle LICY (NYSE) #Cylib #Altilium Group Ltd. UK Scandinavian Enviro Systems AB Climate One Pty Ltd.
Allegrow Biotech Hong Kong #GreatBayBio Bioeconomy Corp. #Acepodia Heartseed
egal.space/blog/investi...
#LiCycle LICY (NYSE) #Cylib #Altilium Group Ltd. UK Scandinavian Enviro Systems AB Climate One Pty Ltd.
Allegrow Biotech Hong Kong #GreatBayBio Bioeconomy Corp. #Acepodia Heartseed
egal.space/blog/investi...
Check it out! The team at Acepodia reports efficacy of cetuximab-conjugated allogenic gamma/delta-T cells against EGFR+ tumors in mice, off-the-shelf, safer alternative to CAR-T. Currently in phase 1 clinical study (NCT06415487). Cell-surface chemistry for the win 👏
jitc.bmj.com/content/13/7...
jitc.bmj.com/content/13/7...
Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors
Background Targeting epidermal growth factor receptor (EGFR) has become a strategic approach in cancer therapy, using various modalities including chimeric antigen receptor (CAR)-αβT cell therapies. D...
jitc.bmj.com
September 12, 2025 at 5:18 AM
Check it out! The team at Acepodia reports efficacy of cetuximab-conjugated allogenic gamma/delta-T cells against EGFR+ tumors in mice, off-the-shelf, safer alternative to CAR-T. Currently in phase 1 clinical study (NCT06415487). Cell-surface chemistry for the win 👏
jitc.bmj.com/content/13/7...
jitc.bmj.com/content/13/7...
Acepodia Unveils Promising Preclinical Findings for Innovative Antibody-Drug Conjugate Technology#USA#Chicago#Cancer_Research#ADC_technology#Acepodia
Acepodia Unveils Promising Preclinical Findings for Innovative Antibody-Drug Conjugate Technology
Acepodia presents exciting preclinical results for their dual-payload antibody-drug conjugate technology at the AACR Annual Meeting 2025. This innovation showcases significant potential in cancer treatment.
third-news.com
April 21, 2025 at 11:07 AM
Acepodia Unveils Promising Preclinical Findings for Innovative Antibody-Drug Conjugate Technology#USA#Chicago#Cancer_Research#ADC_technology#Acepodia